These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 14595819)
1. Microarrays of tumor cell derived proteins uncover a distinct pattern of prostate cancer serum immunoreactivity. Bouwman K; Qiu J; Zhou H; Schotanus M; Mangold LA; Vogt R; Erlandson E; Trenkle J; Partin AW; Misek D; Omenn GS; Haab BB; Hanash S Proteomics; 2003 Nov; 3(11):2200-7. PubMed ID: 14595819 [TBL] [Abstract][Full Text] [Related]
2. Integral protein microarrays for the identification of lung cancer antigens in sera that induce a humoral immune response. Madoz-Gúrpide J; Kuick R; Wang H; Misek DE; Hanash SM Mol Cell Proteomics; 2008 Feb; 7(2):268-81. PubMed ID: 17916591 [TBL] [Abstract][Full Text] [Related]
3. Prostate cancer-associated autoantibodies in serum against tumor-associated antigens as potential new biomarkers. Ummanni R; Duscharla D; Barett C; Venz S; Schlomm T; Heinzer H; Walther R; Bokemeyer C; Brümmendorf TH; Murthy PV; Balabanov S J Proteomics; 2015 Apr; 119():218-29. PubMed ID: 25724726 [TBL] [Abstract][Full Text] [Related]
4. Antibody microarray profiling of human prostate cancer sera: antibody screening and identification of potential biomarkers. Miller JC; Zhou H; Kwekel J; Cavallo R; Burke J; Butler EB; Teh BS; Haab BB Proteomics; 2003 Jan; 3(1):56-63. PubMed ID: 12548634 [TBL] [Abstract][Full Text] [Related]
5. Fingerprinting the circulating repertoire of antibodies from cancer patients. Mintz PJ; Kim J; Do KA; Wang X; Zinner RG; Cristofanilli M; Arap MA; Hong WK; Troncoso P; Logothetis CJ; Pasqualini R; Arap W Nat Biotechnol; 2003 Jan; 21(1):57-63. PubMed ID: 12496764 [TBL] [Abstract][Full Text] [Related]
6. Humoral immune responses to testis antigens in sera from patients with prostate cancer. Hoeppner LH; Dubovsky JA; Dunphy EJ; McNeel DG Cancer Immun; 2006 Jan; 6():1. PubMed ID: 16401063 [TBL] [Abstract][Full Text] [Related]
7. Evaluation and characterization of anti-RalA autoantibody as a potential serum biomarker in human prostate cancer. Li J; Dai L; Lei N; Xing M; Li P; Luo C; Casiano CA; Zhang JY Oncotarget; 2016 Jul; 7(28):43546-43556. PubMed ID: 27286458 [TBL] [Abstract][Full Text] [Related]
8. The prostate cancer immunome: In silico functional analysis of antigenic proteins from microarray profiling with IgG. Luna-Coronell JA; Vierlinger K; Gamperl M; Hofbauer J; Berger I; Weinhäusel A Proteomics; 2016 Apr; 16(8):1204-14. PubMed ID: 27089054 [TBL] [Abstract][Full Text] [Related]
9. Autoantibody biomarkers for the detection of serous ovarian cancer. Katchman BA; Chowell D; Wallstrom G; Vitonis AF; LaBaer J; Cramer DW; Anderson KS Gynecol Oncol; 2017 Jul; 146(1):129-136. PubMed ID: 28427776 [TBL] [Abstract][Full Text] [Related]
10. Standard treatments induce antigen-specific immune responses in prostate cancer. Nesslinger NJ; Sahota RA; Stone B; Johnson K; Chima N; King C; Rasmussen D; Bishop D; Rennie PS; Gleave M; Blood P; Pai H; Ludgate C; Nelson BH Clin Cancer Res; 2007 Mar; 13(5):1493-502. PubMed ID: 17332294 [TBL] [Abstract][Full Text] [Related]
11. Profiling of antibody production against xenograft-released proteins by protein microarrays discovers prostate cancer markers. Jansen FH; van Rijswijk A; Teubel W; van Weerden WM; Reneman S; van den Bemd GJ; Roobol MJ; Bangma CH; Staal FJ; Jenster G J Proteome Res; 2012 Feb; 11(2):728-35. PubMed ID: 22136385 [TBL] [Abstract][Full Text] [Related]
12. Autoantibody Landscape in Patients with Advanced Prostate Cancer. Chen WS; Haynes WA; Waitz R; Kamath K; Vega-Crespo A; Shrestha R; Zhang M; Foye A; Baselga Carretero I; Perez Garcilazo I; Zhang M; Zhao SG; Sjöström M; Quigley DA; Chou J; Beer TM; Rettig M; Gleave M; Evans CP; Lara P; Chi KN; Reiter RE; Alumkal JJ; Ashworth A; Aggarwal R; Small EJ; Daugherty PS; Ribas A; Oh DY; Shon JC; Feng FY Clin Cancer Res; 2020 Dec; 26(23):6204-6214. PubMed ID: 32967941 [TBL] [Abstract][Full Text] [Related]
13. The identification of auto-antibodies in pancreatic cancer patient sera using a naturally fractionated Panc-1 cell line. Li C; Kim HY; Vuong H; Patwa T; Pal M; Brand RE; Simeone DM; Lubman DM Cancer Biomark; 2010; 7(1):25-37. PubMed ID: 21045262 [TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen. Improving its ability to diagnose early prostate cancer. Oesterling JE JAMA; 1992 Apr 22-29; 267(16):2236-8. PubMed ID: 1372945 [No Abstract] [Full Text] [Related]
15. Development of monoclonal antibody imaging of metastatic prostatic carcinoma. Meyers FJ; Denardo SJ; Macey D; White RD; Unger M Prostate; 1989; 14(3):209-20. PubMed ID: 2471962 [TBL] [Abstract][Full Text] [Related]
16. Novel potential serological prostate cancer biomarkers using CT100+ cancer antigen microarray platform in a multi-cultural South African cohort. Adeola HA; Smith M; Kaestner L; Blackburn JM; Zerbini LF Oncotarget; 2016 Mar; 7(12):13945-64. PubMed ID: 26885621 [TBL] [Abstract][Full Text] [Related]
17. Detection of prostate cancer with a blood-based assay for early prostate cancer antigen. Paul B; Dhir R; Landsittel D; Hitchens MR; Getzenberg RH Cancer Res; 2005 May; 65(10):4097-100. PubMed ID: 15899799 [TBL] [Abstract][Full Text] [Related]
19. Development of natural protein microarrays for diagnosing cancer based on an antibody response to tumor antigens. Qiu J; Madoz-Gurpide J; Misek DE; Kuick R; Brenner DE; Michailidis G; Haab BB; Omenn GS; Hanash S J Proteome Res; 2004; 3(2):261-7. PubMed ID: 15113102 [TBL] [Abstract][Full Text] [Related]
20. Monoclonal antibody that defines the prostate specific antigen. Donn F; Bruns T; von Meyerinck L; Schulz M; Becker WM; Becker H; Klosterhalfen H Prostate; 1989; 14(3):237-49. PubMed ID: 2471963 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]